# Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer

> **NCT00052559** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 32 (actual)

## Conditions studied

- Adenocarcinoma of the Rectum
- Stage II Rectal Cancer
- Stage III Rectal Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** fluorouracil
- **RADIATION:** external beam radiation therapy
- **PROCEDURE:** therapeutic conventional surgery
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00052559
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** 2003-04
- **Final completion:** —
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2013-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00052559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00052559, "Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00052559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*